Novo Nordisk And Shanghai Institute For Biological Sciences Jointly Set Up Research Center For Pre-diabetes
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk and Chinese Academy of Science's Shanghai Institute for Biological Sciences recently inaugurated a research center for pre-diabetes in Shanghai. China's first such facility, the joint venture will bring diabetes prevention to the pre-development stage of the disease. The center will initiate early monitoring and intervention in individuals who are at high risk of developing diabetes during the pre-clinical reversible stage. Individuals' samples and data will be collected during clinics and community follow-up. The research will focus on molecular mechanism and markers in the development of obesity and diabetes, as well as explore nutritional intervention methods and lifestyle changes to slow the disease. (Click here for more - Chinese Language)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.